Table 3 Age-adjusted anti-HEV-IgG seroprevalence in the study population and control group characterized in Table 1
From: Hepatitis E virus as a trigger for Guillain-Barré syndrome
Age group | GBS: n(%) | Healthy controls: n(%) | P valuea |
|---|---|---|---|
18–19 | 0/3 (0) | 0/2 (0) | 1 |
20–29 | 1/12 (8) | 18/149 (12) | 1 |
30–39 | 2/15 (13) | 7/45 (16) | 1 |
40–49 | 9/20 (45) | 4/20 (20) | .176 |
50–59 | 15/34 (44) | 10/31 (32) | .445 |
60–69 | 19/35 (54) | 4/9 (44) | .716 |
70–79 | 16/32 (50) | 1/2 (50) | 1 |
80–89 | 5/12 (42) | 1/5 (20) | .600 |